retatrutide news today october 2025 Retatrutide: What It Is & How This New Drug Works FDA Warns Companies Over Compounded

Low suspicion for disseminated intravascular coagulation (DIC) with largely unremarkable coagulation panel (PT/INR 15.9 seconds/1.3, aPTT 32.9 seconds, and fibrinogen 366 mg/dL), thrombotic thrombocytopenic purpura (TTP) with normal ADAMTS13 activity 86% and antibody levels 3, and other forms of thrombotic microangiopathy (TMA) with no significant schistocytes on peripheral blood smear, negative direct anti-globuin test (DAT), normal complement levels and kidney function

Reference #18.11ff1302.1785093008.3fef855a

There is currently no scientific evidence to suggest that Ozempic or other GLP-1 medications cause the development of Irritable Bowel Syndrome

Herman et al